Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03900026 · ClinicalTrials.gov registry record · Phase 4
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
A Phase 4 study of Atherosclerosis and Vein Occlusion, sponsored by Unity Health Toronto.
- Completed
- Registry status
- Phase 4
- Development phase
- 782
- Enrollment target
- 20
- Study locations
NCT03900026 is a Phase 4 study of Atherosclerosis and Vein Occlusion that has completed, run by Unity Health Toronto. The registered enrollment target is 782 participants, below the 1,054-participant average among 69 other Atherosclerosis trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03900026, a Phase 4 study of Atherosclerosis and Vein Occlusion, has completed, sponsored by Unity Health Toronto.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 782 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Evolocumab
Study Locations (20)
Other
- Royal Adelaide Hospital - Adelaide
- Flinders Medical Centre - Bedford Park
- Monash University - Melbourne
- Fiona Stanley Hospital - Murdoch
- Foothills Medical Centre - Calgary
- Medical Centre Hungarian Defence Forces - Budapest
Ontario
- Hamilton Health Sciences - Hamilton
- Kingston Health Sciences Centre - Kingston
- One Heart Care - Mississauga
- North York Diagnostic and Cardiology Centre - North York
- Sunnybrook Health Sciences Center - North York
- St. Michael's Hospital - Toronto
California
- San Francisco VA Medical Center - San Francisco
Florida
- Jacksonville Center for Clinical Research - Jacksonville
Maine
- Maine Medical Center - Portland
Minnesota
- Minneapolis Heart Institute Foundation - Minneapolis
Ohio
- University Hospital Cleveland Medical Center - Cleveland
Alberta
- University of Alberta - Edmonton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 782 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03900026
The ClinicalTrials.gov registry entry for NCT03900026 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 782 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,054-participant average among 69 other Atherosclerosis trials with a reported enrollment target (26% lower). The listed sponsor is Unity Health Toronto, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03900026 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT03900026 about?
NCT03900026 is a clinical study titled "Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery". The purpose of this study is to determine if evolocumab added to regular statin therapy improves vein graft patency after coronary artery bypass graft (CABG) surgery.
What is the current status of trial NCT03900026?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 782 participants. The study started on 2019-05-30. Estimated completion is 2025-01-30.
What conditions does trial NCT03900026 study?
This clinical trial studies the following conditions: Atherosclerosis, Vein Occlusion, Coronary Artery Bypass Graft Surgery.
What interventions are being tested in trial NCT03900026?
The interventions under investigation include: Placebo (OTHER), Evolocumab (DRUG).
Who is sponsoring clinical trial NCT03900026?
This trial is sponsored by Unity Health Toronto, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03900026 being conducted?
This trial has 20 study locations across California, Florida, Maine, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RECRUITING · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
-
Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.